299
Views
17
CrossRef citations to date
0
Altmetric
Letter

Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia

&
Pages 1617-1619 | Received 20 Dec 2011, Accepted 31 Dec 2011, Published online: 31 Jan 2012

References

  • Karen CC, John GB. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 2011;65:501–521.
  • Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis 2011;24:370–376.
  • Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005;49:3529–3532.
  • Freifeld AG, Bow EJ, Sepkowitz KA, . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56–e93.
  • Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011;53(Suppl. 1):S4–S7.
  • Dellit TH, Owens RC, McGowan JE Jr, . Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.
  • Heard SR, Wren B, Barnett MJ, . Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol Infect 1988;100:63–72.
  • Rampling A, Warren RE, Bevan PC, . Clostridium difficile in haematological malignancy. J Clin Pathol 1985;38:445–451.
  • Panichi G, Pantosti A, Gentile G, . Clostridium difficile colitis in leukemia patients. Eur J Cancer Clin Oncol 1985;21:1159–1163.
  • Morris JG Jr, Jarvis WR, Nunez-Montiel OL, . Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders. Arch Intern Med 1984;144:967–969.
  • Hornbuckle K, Chak A, Lazarus HM, . Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998;9:307–311.
  • Loo VG, Bourgault AM, Poirier L, . Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693–1703.
  • Paul M, Yahav D, Bivas A, . Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010;(11):CD005197.
  • von Baum H, Sigge A, Bommer M, . Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006;58:891–894.
  • Slavin MA, Lingaratnam S, Mileshkin L, . Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011;41:102–109.
  • Chapin KC, Dickenson RA, Wu F, . Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn 2011;13:395–400.
  • Schalk E, Bohr UR, Konig B, . Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2009;89:9–14.
  • Gorschluter M, Glasmacher A, Hahn C, . Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001;33:786–791.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.